Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Celularity Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CELU
Nasdaq
8731
https://celularity.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Celularity Inc
Celularity Inc. to Host Investor and Analyst Research & Development Day
- Apr 22nd, 2024 12:00 pm
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
- Apr 19th, 2024 9:30 pm
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
- Apr 18th, 2024 8:30 pm
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
- Apr 15th, 2024 12:00 pm
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
- Apr 8th, 2024 1:00 pm
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
- Mar 26th, 2024 1:00 pm
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
- Mar 20th, 2024 1:15 pm
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
- Mar 14th, 2024 1:15 pm
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
- Mar 12th, 2024 1:20 pm
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
- Mar 7th, 2024 2:35 pm
Celularity Announces 1-for-10 Reverse Stock Split
- Feb 23rd, 2024 9:10 pm
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
- Feb 14th, 2024 9:05 pm
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline
- Feb 1st, 2024 2:00 pm
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
- Jan 25th, 2024 2:00 pm
Celularity Releases CEO Letter to Shareholders
- Jan 18th, 2024 6:40 pm
Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare
- Jan 4th, 2024 6:00 pm
Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023
- Jan 3rd, 2024 5:00 pm
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification
- Oct 18th, 2023 1:00 pm
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
- Sep 7th, 2023 8:10 pm
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
- Aug 29th, 2023 1:00 pm
Scroll